- Home
- » Tags
- » Larotrectinib
Top View
- Targeted/Precision Therapies Beyond EGFR and ALK Alterations
- Malignant, Locally Aggressive Connective Tissue Tumours
- Vitrakvi; INN-Larotrectinib
- Oncology Oral, Other Therapeutic Class Review
- Neurotrophic Receptor Tyrosine Kinase (NRTK) Inhibitors – Unified Formulary
- Canadian Consensus for Biomarker Testing and Treatment of TRK
- 210861Orig1s000 211710Orig1s000
- Medicolegal Issues During the COVID-19 Pandemic
- Numab Ono 2017
- Agnostic-Histology Approval of New Drugs in Oncology
- Targeted Therapy in Advanced and Metastatic Non-Small Cell Lung Cancer
- Evidence Dossier
- Clinical Criteria, Step Therapy, and Quantity Limits for Tenncare Preferred Drug List (PDL) September 1, 2021
- NCCN Guidelines for Colon Cancer and Rectal Cancer 1.2019 – Follow-Up on 02/27/19
- Spotlight on NTRK Gene Fusions: Tumor-Agnostic Cancer Therapies and the Importance of Testing
- Recurrent Glioblastoma: from Molecular Landscape to New Treatment Perspectives
- Virtual Molecular Tumor Board: Recognition and Management of Targetable Tumor Mutations in Less Common Cancer Types
- Breast Cancer (Recurrent Or Metastatic) Treatment Regimens
- (BPCA) Written Requests for Oncology Products Denise Casey, MD March 15, 2019 Goals of a Pediatric Development Program
- Advancing Health Through Innovation: New Drug Approvals 2019
- Oncology Agents Policy #: Rx.01.67
- Proton Pump Inhibitors and Oncologic Treatment Efficacy
- Tumour-Agnostic Therapies
- Precision Medicine in Oncology: a Review of Multi-Tumor Actionable Molecular Targets with an Emphasis on Non-Small Cell Lung Cancer
- List of Cleared Or Approved Companion Diagnostic Devices (In Vitro and Imaging Tools)
- TRK Inhibitors: Clinical Development of Larotrectinib
- Larotrectinib) Capsules, for Oral Use • Embryo-Fetal Toxicity: Can Cause Fetal Harm
- CVS Caremark® Value Formulary Effective As of 07/01/2021
- And RET-Fusion-Directed Therapy in Pediatric Thyroid Cancer Yields
- Selpercatinib Aimed at RET-Altered Cancers
- Activity of Larotrectinib in Patients with Advanced TRK Fusion Thyroid Cancer
- Tropomyosin Receptor Kinase Inhibitors for the Treatment of TRK Fusion Cancer
- Colon Cancer Data Key As Pfizer Buys Array
- Pharmacokinetic Targets for Therapeutic Drug Monitoring of Small Molecule Kinase Inhibitors in Pediatric Oncology Julie M
- Mechanisms of Resistance to NTRK Inhibitors and Therapeutic Strategies in NTRK1-Rearranged Cancers Miho J
- Vitrakvi® (Larotrectinib) (Oral) Document Number: IH-0420 Last Review Date: 07/01/2021 Date of Origin: 01/03/2019 Dates Reviewed: 01/2019, 05/2019, 07/2020, 07/2021
- (Vitrakvi) for Neurotrophic Tyrosine Receptor Kinase (NTRK) Positive Solid Tumours
- 2021 Pacificsource Health Plans Prior Authorization Criteria Last Modified
- NTRK Gene Fusions and TRK Inhibitors Blueprint
- Cogent Biosciences Provides Corporate Updates and Reports First Quarter 2021 Financial Results
- NTRK Kinase Domain Mutations in Cancer Variably Impact Sensitivity to Type I and Type II Inhibitors
- Tyrosine Kinase Receptors in Oncology
- Thyroid Carcinoma Treatment Regimens